Sana Health

Sana Health operates at the intersection of medical devices, wearables, digital health, and clinical research. Its differentiation is the combination of audiovisual stimulation, neuromodulation patterns, and biometric sensing in a wearable system, supported by the Sana Device and Sana Relief App. That positioning gives the company a broader therapeutic scope than a conventional wellness wearable: its stated applications include anxiety, pain, physical recovery, mental well-being, and rest. The company’s clinical emphasis, including work involving fibromyalgia, neuropathic pain, anxiety, and PTSD, also separates it from consumer relaxation products that lack a medical-device development pathway. Sana has raised $23.9 million across 16 recorded rounds and remains a private company with an indicated employee range of 11-50. Its market position is therefore best characterized as an early-stage, clinically oriented neuromodulation entrant rather than an established scaled device manufacturer.

Sana Health’s trajectory shows a progression from founder-led technology development toward clinical validation and regulatory positioning. Founded in 2015, the company’s early disclosed financing included a $4.28 million seed round in 2018 and a $4.02 million convertible note in 2019 led by Founders Fund. It added a $1.8 million seed round in 2020, a $5.8 million seed round later that year, and a $4.2 million convertible note led by Noetic Fund on Sep 1, 2021. The company reports 16 total funding rounds and $23.9 million in aggregate funding, although several rounds have no disclosed amount in the detailed record. Product development expanded from the Sana Device to the connected Sana Relief App, while clinical ambitions broadened from anxiety and pain relief to fibromyalgia, neuropathic pain, and PTSD. Patent activity in 2023-2024 suggests continued investment in brain stimulation and fibromyalgia applications. The main inflection point is the shift from early therapeutic concept and grant-supported work toward pivotal studies and breakthrough-device efforts. No post-2021 financing or hiring growth is disclosed, so scale-up remains unconfirmed.